Drug Trial Radar · NCT04919226
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
Last checked: Nov 20, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
259
Actual
Start
Dec 21, 2021
Primary completion
Jun 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- ITM Solucin GmbHIndustry
- Sponsor type
- Industry
- First posted
- Jun 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the efficacy, safety \& patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in patients with well-differentiated aggressive grade 2 and grade 3, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin.
Conditions
- Neuroendocrine Tumors
Interventions
177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRTDrug
Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-edotreotide with a defined number of cycles will be administered.
CAPTEM (Capecitabine and Temozolomide)Drug
Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
Amino-Acid SolutionOther
The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
EverolimusDrug
Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)Drug
Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free SurvivalTime frame: Every 12 weeks from randomization until disease progression or death whichever occurs earlier, during the time necessary to observe 148 Progression Free Survival (PFS) events.
Locations
42 sites in 10 countries. Site status is shown where the registry gives one.
Stanford Cancer Center
Palo Alto, California
University of Colorado Hospital, Nuclear Medicine
Aurora, Colorado
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida
Dana Farber Cancer Institute
Boston, Massachusetts
Mayo Clinic - Rochester, Department of Oncology
Rochester, Minnesota
Washington University Alvin J. Siteman Cancer Center
St Louis, Missouri
Memorial Sloan-Kettering Cancer Center
New York, New York
ICAHN School of Medicine at Mount Sinai, Tish Cancer Institute
New York, New York
Duke University School of Medicine, Duke Cancer Institute
Durham, North Carolina
Oregon Health and Science University
Portland, Oregon
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Texas Oncology
Dallas, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah
Royal North Shore Hospital
St Leonards, New South Wales, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Fudan University Shanghai Cancer Center
Shanghai, China
Affiliated Hospital of Jiangnan University
Wuxi, China
Edouard Herriot Hospital, Medical Oncology Unit
Lyon, France
IUCT Oncopole - Institut Universitaire du Cancer de Toulouse
Toulouse, France
Haut-Leveque Hospital, Department of Hepatogastroenterology and Digestive Tract Oncology
Pessac, Bordeaux, France
Nantes University Hospital Center - Hotel Dieu Hospital
Nantes, Cedex, France
Charite - University Hospital Berlin
Berlin, Germany
University Hospital Bonn, Department of Nuclear Medicine
Bonn, Germany
University Hospital Erlangen, Department of Internal Medicine I - Endocrinology
Erlangen, Germany
University Duisburg-Essen, University Hospital Essen, Clinic for Nuclear Medicine
Essen, Germany
Tata Memorial Hospital, Nuclear Medicine & Molecular Imaging
Mumbai, India
HCG Cancer Centre, Medical Oncology
Bangalore, Karnataka, India
All India Institute Of Medical Sciences, Nuclear Medicine
New Delhi, National Capital Territory of Delhi, India
University Polyclinic Hospital "G. Martino", Department of Biomedical Sciences, Dentistry and Morphological and Functional Imaging, Complex Operational Unit of Nuclear Medicine
Messina, Italy
European Institute of Oncology (IEO), IRCCS
Milan, Italy
University Polyclinic Foundation "Agostino Gemelli" - IRCCS, Complex Operative Unit of Medical Oncology
Rome, Italy
VU Medical Center (VUMC), Department of Medical Oncology
Amsterdam, Netherlands
Erasmus University Medical Center Rotterdam
Rotterdam, Netherlands
University Hospital Vall d'Hebron, Department of Medical Oncology
Barcelona, Spain
ICO Hospitalet, Catalan Institute of Oncology
Barcelona, Spain
University General Hospital Gregorio Maranon
Madrid, Spain
University Hospital 12 de Octubre, Department of Gastroenterology
Madrid, Spain
Central University Hospital de Asturias (HUCA), IUOPA - Universitary Institute of Oncology
Oviedo, Spain
University Hospital Complex of Santiago (CHUS)
Santiago de Compostela, Spain
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.